<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.biomedcentral.com/feeds/latestarticles/journal?journal=bmcbiotechnol&amp;quantity=&amp;format=rss&amp;version=">
        <title>BMC Biotechnology - Latest Articles</title>
        <link>http://www.biomedcentral.com/bmcbiotechnol/</link>
        <description>The latest research articles published by BMC Biotechnology</description>
        <dc:date>2009-11-25T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6750/9/97" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6750/9/96" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6750/9/95" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6750/9/94" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6750/9/93" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6750/9/92" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6750/9/91" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6750/9/90" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6750/9/89" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6750/9/88" />
                            </rdf:Seq>
        </items>
        <extra:info rdf:parseType="Literal">
            <html:div style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif" xmlns:html="http://www.w3.org/1999/xhtml">
                <html:span style="font-weight:bold">
                    This is an RSS newsfeed from BioMed Central
                </html:span>
                <html:br />
                <html:span style="font-size: 12px;">
                    It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit
                    <html:br />
                    <html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">
                        http://www.biomedcentral.com/info/about/rss/
                    </html:a>
                    <html:br />
                </html:span>
            </html:div>
        </extra:info>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.biomedcentral.com/1472-6750/9/97">
        <title>A rapid and inexpensive labeling method for microarray gene expression analysis</title>
        <description>Background:
Global gene expression profiling by DNA microarrays is an invaluable tool in biological research.  However, existing labeling methods are time consuming and costly and therefore often limit the scale of microarray experiments and sample throughput. Here we introduce a new, fast, inexpensive method for direct random-primed fluorescent labeling of eukaryotic cDNA for gene expression analysis and compare the results obtained on the NimbleGen microarray platform with two other widely-used labeling methods, namely the NimbleGen-recommended double-stranded cDNA protocol and the indirect (aminoallyl) method.
Results:
Two total RNA samples were labeled with each method and hybridized to NimbleGen expression arrays.  Although all methods tested here provided similar global results and biological conclusions, the new direct random-primed cDNA labeling method provided slightly better correlation between replicates compared to the other methods and thus increased ability to find statistically significant differentially expressed genes.
Conclusion:
The new direct random-primed cDNA labeling method introduced here is suitable for gene expression microarrays and provides a rapid, inexpensive alternative to existing methods. Using NimbleGen microarrays, the method produced excellent results comparable to those obtained with other methods. However, the simplicity and cost-effectiveness of the new method allows for increased sample throughput in microarray experiments and makes the process amenable to automation with a relatively simple liquid handling system.</description>
        <link>http://www.biomedcentral.com/1472-6750/9/97</link>
                <dc:creator>Mario Ouellet</dc:creator>
                <dc:creator>Paul Adams</dc:creator>
                <dc:creator>Jay Keasling</dc:creator>
                <dc:creator>Aindrila Mukhopadhyay</dc:creator>
                <dc:source>BMC Biotechnology 2009, 9:97</dc:source>
        <dc:date>2009-11-25T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6750-9-97</dc:identifier>
        <prism:publicationName>BMC Biotechnology</prism:publicationName>
        <prism:issn>1472-6750</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>97</prism:startingPage>
        <prism:publicationDate>2009-11-25T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6750/9/96">
        <title>High-level HIV-1 Nef transient expression in Nicotiana benthamiana using the P19 gene silencing suppressor protein of Artichoke Mottled Crinckle Virus </title>
        <description>Background:
In recent years, different HIV antigens have been successfully expressed in plants by either stable transformation or transient expression systems. Among HIV proteins, Nef is considered a promising target for the formulation of a multi-component vaccine due to its implication in the first steps of viral infection. Attempts to express Nef as a single protein product (not fused to a stabilizing protein) in transgenic plants resulted in disappointingly low yields (about 0.5% of total soluble protein). In this work we describe a transient expression system based on co-agroinfiltration of plant virus gene silencing suppressor proteins in Nicotiana benthamiana, followed by a two-step affinity purification protocol of plant-derived Nef.
Results:
The effect of three gene silencing viral suppressor proteins (P25 of Potato Virus X, P19 of either Artichoke Mottled Crinckle virus and Tomato Bushy Stunt virus) on Nef transient expression yield was evaluated. The P19 protein of Artichoke Mottled Crinckle virus (AMCV-P19) gave the highest expression yield in vacuum co-agroinfiltration experiments reaching 1.3% of total soluble protein, a level almost three times higher than that previously reported in stable transgenic plants. The high yield observed in the co-agroinfiltrated plants was correlated to a remarkable decrease of Nef-specific small interfering RNAs (siRNAs) indicating an effective modulation of RNA silencing mechanisms by AMCV-P19. Interestingly, we also showed that expression levels in top leaves of vacuum co-agroinfiltrated plants were noticeably reduced compared to bottom leaves. Moreover, purification of Nef from agroinfiltrated tissue was achieved by a two-step immobilized metal ion affinity chromatography protocol with yields of 250 ng/g of fresh tissue.
Conclusion:
We demonstrated that expression level of HIV-1 Nef in plant can be improved using a transient expression system enhanced by the AMCV-P19 gene silencing suppressor protein. Moreover, plant-derived Nef was purified, with enhanced yield, exploiting a two-step purification protocol. These results represent a first step towards the development of a plant-derived HIV vaccine.</description>
        <link>http://www.biomedcentral.com/1472-6750/9/96</link>
                <dc:creator>Raffaele Lombardi</dc:creator>
                <dc:creator>Patrizia Circelli</dc:creator>
                <dc:creator>Maria Elena Villani</dc:creator>
                <dc:creator>Giampaolo Buriani</dc:creator>
                <dc:creator>Luca Nardi</dc:creator>
                <dc:creator>Valentina Coppola</dc:creator>
                <dc:creator>Linda Bianco</dc:creator>
                <dc:creator>Eugenio Benvenuto</dc:creator>
                <dc:creator>Marcello Donini</dc:creator>
                <dc:creator>Carla Marusic</dc:creator>
                <dc:source>BMC Biotechnology 2009, 9:96</dc:source>
        <dc:date>2009-11-20T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6750-9-96</dc:identifier>
        <prism:publicationName>BMC Biotechnology</prism:publicationName>
        <prism:issn>1472-6750</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>96</prism:startingPage>
        <prism:publicationDate>2009-11-20T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6750/9/95">
        <title>Quantifying and resolving multiple vector transformants in S. cerevisiae plasmid libraries</title>
        <description>Background:
In addition to providing the molecular machinery for transcription and translation, recombinant microbial expression hosts maintain the critical genotype-phenotype link that is essential for high throughput screening and recovery of proteins encoded by plasmid libraries. It is known that Escherichia coli cells can be simultaneously transformed with multiple unique plasmids and thusly complicate recombinant library screening experiments. As a result of their potential to yield misleading results, bacterial multiple vector transformants have been thoroughly characterized in previous model studies. In contrast to bacterial systems, there is little quantitative information available regarding multiple vector transformants in yeast. Saccharomyces cerevisiae is the most widely used eukaryotic platform for cell surface display, combinatorial protein engineering, and other recombinant library screens. In order to characterize the extent and nature of multiple vector transformants in this important host, plasmid-born gene libraries constructed by yeast homologous recombination were analyzed by DNA sequencing.
Results:
It was found that up to 90% of clones in yeast homologous recombination libraries may be multiple vector transformants, that on average these clones bear four or more unique mutant genes, and that these multiple vector cells persist as a significant proportion of library populations for greater than 24 hours during liquid outgrowth. Both vector concentration and vector to insert ratio influenced the library proportion of multiple vector transformants, but their population frequency was independent of transformation efficiency. Interestingly, the average number of plasmids born by multiple vector transformants did not vary with their library population proportion.
Conclusion:
These results highlight the potential for multiple vector transformants to dominate yeast libraries constructed by homologous recombination. The previously unrecognized prevalence and persistence of multiply transformed yeast cells have important implications for yeast library screens. The quantitative information described herein should increase awareness of this issue, and the rapid sequencing approach developed for these studies should be widely useful for identifying multiple vector transformants and avoiding complications associated with cells that have acquired more than one unique plasmid.</description>
        <link>http://www.biomedcentral.com/1472-6750/9/95</link>
                <dc:creator>Thomas Scanlon</dc:creator>
                <dc:creator>Elizabeth Gray</dc:creator>
                <dc:creator>Karl Griswold</dc:creator>
                <dc:source>BMC Biotechnology 2009, 9:95</dc:source>
        <dc:date>2009-11-20T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6750-9-95</dc:identifier>
        <prism:publicationName>BMC Biotechnology</prism:publicationName>
        <prism:issn>1472-6750</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>95</prism:startingPage>
        <prism:publicationDate>2009-11-20T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6750/9/94">
        <title>Non-antibiotic selection systems for soybean somatic embryos: 
the lysine analog aminoethyl-cysteine as a selection agent</title>
        <description>Background:
In soybean somatic embryo transformation, the standard selection agent currently used is hygromycin. It may be preferable to avoid use of antibiotic resistance genes in foods. The objective of these experiments was to develop a selection system for producing transgenic soybean somatic embryos without the use of antibiotics such as hygromycin.
Results:
When tested against different alternate selection agents our studies show that 0.16 &#956;g/mL glufosinate, 40 mg/L isopropylamine-glyphosate, 0.5 mg/mL (S-(2 aminoethyl)-L-cysteine) (AEC) and the acetolactate synthase (ALS) inhibitors Exceed&#174; and Synchrony&#174; both at 150 &#956;g/mL inhibited soybean somatic embryo growth. Even at the concentration of 2 mg/mL, lysine+threonine (LT) were poor selection agents. The use of AEC may be preferable since it is a natural compound. Unlike the plant enzyme, dihydrodipicolinate synthase (DHPS) from E. coli is not feed-back inhibited by physiological concentrations of lysine. The dapA gene which codes for E. coli DHPS was expressed in soybean somatic embryos under the control of the CaMV 35S promoter. Following introduction of the construct into embryogenic tissue of soybean, transgenic events were recovered by incubating the tissue in liquid medium containing AEC at a concentration of 5 mM. Only transgenic soybeans were able to grow at this concentration of AEC; no escapes were observed.
Conclusion:
Genetically engineered soybeans expressing a lysine insensitive DHPS gene can be selected with the non-antibiotic selection agent AEC. We also report here the inhibitory effects of glufosinate, (isopropylamine-glyphosate) (Roundup&#174;), AEC and the ALS inhibitors Exceed&#174; and Synchrony&#174; against different tissues of soybean</description>
        <link>http://www.biomedcentral.com/1472-6750/9/94</link>
                <dc:creator>Suryadevara Rao</dc:creator>
                <dc:creator>Lewamy Mamadou</dc:creator>
                <dc:creator>Matt McConnell</dc:creator>
                <dc:creator>Raghuveer Polisetty</dc:creator>
                <dc:creator>Prachuab Kwanyuen</dc:creator>
                <dc:creator>David Hildebrand</dc:creator>
                <dc:source>BMC Biotechnology 2009, 9:94</dc:source>
        <dc:date>2009-11-18T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6750-9-94</dc:identifier>
        <prism:publicationName>BMC Biotechnology</prism:publicationName>
        <prism:issn>1472-6750</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>94</prism:startingPage>
        <prism:publicationDate>2009-11-18T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6750/9/93">
        <title>Genetic load and transgenic mitigating genes in transgenic Brassica rapa (field mustard) x Brassica napus (oilseed rape) hybrid populations</title>
        <description>Background:
One theoretical explanation for the relatively poor performance of Brassica rapa (weed) &#215; Brassica napus (crop) transgenic hybrids suggests that hybridization imparts a negative genetic load. Consequently, in hybrids genetic load could overshadow any benefits of fitness enhancing transgenes and become the limiting factor in transgenic hybrid persistence. Two types of genetic load were analyzed in this study: random/linkage-derived genetic load, and directly incorporated genetic load using a transgenic mitigation (TM) strategy. In order to measure the effects of random genetic load, hybrid productivity (seed yield and biomass) was correlated with crop- and weed-specific AFLP genomic markers. This portion of the study was designed to answer whether or not weed &#215; transgenic crop hybrids possessing more crop genes were less competitive than hybrids containing fewer crop genes. The effects of directly incorporated genetic load (TM) were analyzed through transgene persistence data. TM strategies are proposed to decrease transgene persistence if gene flow and subsequent transgene introgression to a wild host were to occur.
Results:
In the absence of interspecific competition, transgenic weed &#215; crop hybrids benefited from having more crop-specific alleles. There was a positive correlation between performance and number of B. napus crop-specific AFLP markers [seed yield vs. marker number (r = 0.54, P = 0.0003) and vegetative dry biomass vs. marker number (r = 0.44, P = 0.005)]. However under interspecific competition with wheat or more weed-like conditions (i.e. representing a situation where hybrid plants emerge as volunteer weeds in subsequent cropping systems), there was a positive correlation between the number of B. rapa weed-specific AFLP markers and seed yield (r = 0.70, P = 0.0001), although no such correlation was detected for vegetative biomass. When genetic load was directly incorporated into the hybrid genome, by inserting a fitness-mitigating dwarfing gene that that is beneficial for crops but deleterious for weeds (a transgene mitigation measure), there was a dramatic decrease in the number of transgenic hybrid progeny persisting in the population.
Conclusion:
The effects of genetic load of crop and in some situations, weed alleles might be beneficial under certain environmental conditions. However, when genetic load was directly incorporated into transgenic events, e.g., using a TM construct, the number of transgenic hybrids and persistence in weedy genomic backgrounds was significantly decreased.</description>
        <link>http://www.biomedcentral.com/1472-6750/9/93</link>
                <dc:creator>Christy Rose</dc:creator>
                <dc:creator>Reginald Millwood</dc:creator>
                <dc:creator>Hong Seok Moon</dc:creator>
                <dc:creator>Murali Rao</dc:creator>
                <dc:creator>Matthew Halfill</dc:creator>
                <dc:creator>Paul Raymer</dc:creator>
                <dc:creator>Suzanne Warwick</dc:creator>
                <dc:creator>Hani Al-Ahmad</dc:creator>
                <dc:creator>Jonathan Gressel</dc:creator>
                <dc:creator>C Neal Stewart</dc:creator>
                <dc:source>BMC Biotechnology 2009, 9:93</dc:source>
        <dc:date>2009-10-31T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6750-9-93</dc:identifier>
        <prism:publicationName>BMC Biotechnology</prism:publicationName>
        <prism:issn>1472-6750</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>93</prism:startingPage>
        <prism:publicationDate>2009-10-31T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6750/9/92">
        <title>Affinity maturation generates greatly improved xyloglucan-specific carbohydrate binding modules</title>
        <description>Background:
Molecular evolution of carbohydrate binding modules (CBM) is a new approach for the generation of glycan-specific molecular probes. To date, the possibility of performing affinity maturation on CBM has not been investigated. In this study we show that binding characteristics such as affinity can be improved for CBM generated from the CBM4-2 scaffold by using random mutagenesis in combination with phage display technology.
Results:
Two modified proteins with greatly improved affinity for xyloglucan, a key polysaccharide abundant in the plant kingdom crucial for providing plant support, were generated. Both improved modules differ from other existing xyloglucan probes by binding to galactose-decorated subunits of xyloglucan. The usefulness of the evolved binders was verified by staining of plant sections, where they performed better than the xyloglucan-binding module from which they had been derived. They discriminated non-fucosylated from fucosylated xyloglucan as shown by their ability to stain only the endosperm, rich in non-fucosylated xyloglucan, but not the integument rich in fucosylated xyloglucan, on tamarind seed sections.
Conclusion:
We conclude that affinity maturation of CBM selected from molecular libraries based on the CBM4-2 scaffold is possible and has the potential to generate new analytical tools for detection of plant carbohydrates.</description>
        <link>http://www.biomedcentral.com/1472-6750/9/92</link>
                <dc:creator>Laura von Schantz</dc:creator>
                <dc:creator>Fredrika Gullfot</dc:creator>
                <dc:creator>Sebastian Scheer</dc:creator>
                <dc:creator>Lada Filonova</dc:creator>
                <dc:creator>Lavinia Cicortas Gunnarsson</dc:creator>
                <dc:creator>James Flint</dc:creator>
                <dc:creator>Geoffrey Daniel</dc:creator>
                <dc:creator>Eva Nordberg-Karlsson</dc:creator>
                <dc:creator>Harry Brumer</dc:creator>
                <dc:creator>Mats Ohlin</dc:creator>
                <dc:source>BMC Biotechnology 2009, 9:92</dc:source>
        <dc:date>2009-10-31T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6750-9-92</dc:identifier>
        <prism:publicationName>BMC Biotechnology</prism:publicationName>
        <prism:issn>1472-6750</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>92</prism:startingPage>
        <prism:publicationDate>2009-10-31T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6750/9/91">
        <title>Authentication scheme for routine verification of genetically similar laboratory colonies: a trial with Anopheles gambiae </title>
        <description>Background:
When rearing morphologically indistinguishable laboratory strains concurrently, the threat of unintentional genetic contamination is constant. Avoidance of accidental mixing of strains is difficult due to the use of common equipment, technician error, or the possibility of self relocation by adult mosquitoes (&quot;free fliers&quot;). In many cases, laboratory strains are difficult to distinguish because of morphological and genetic similarity, especially when laboratory colonies are isolates of certain traits from the same parental strain, such as eye color mutants, individuals with certain chromosomal arrangements or high levels of insecticide resistance. Thus, proving genetic integrity could seem incredibly time-consuming or impossible. On the other hand, lacking proof of genetically isolated laboratory strains could question the validity of research results.
Results:
We present a method for establishing authentication matrices to routinely distinguish and confirm that laboratory strains have not become physically or genetically mixed through contamination events in the laboratory. We show a specific example with application to Anopheles gambiae sensu stricto strains at the Malaria Research and Reference Reagent Resource Center. This authentication matrix is essentially a series of tests yielding a strain-specific combination of results.
Conclusion:
These matrix-based methodologies are useful for several mosquito and insect populations but must be specifically tailored and altered for each laboratory based on the potential contaminants available at any given time. The desired resulting authentication plan would utilize the least amount of routine effort possible while ensuring the integrity of the strains.</description>
        <link>http://www.biomedcentral.com/1472-6750/9/91</link>
                <dc:creator>Elien Wilkins</dc:creator>
                <dc:creator>Paula Marcet</dc:creator>
                <dc:creator>Alice Sutcliffe</dc:creator>
                <dc:creator>Paul Howell</dc:creator>
                <dc:source>BMC Biotechnology 2009, 9:91</dc:source>
        <dc:date>2009-10-22T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6750-9-91</dc:identifier>
        <prism:publicationName>BMC Biotechnology</prism:publicationName>
        <prism:issn>1472-6750</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>91</prism:startingPage>
        <prism:publicationDate>2009-10-22T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6750/9/90">
        <title>Using a water-immiscible ionic liquid to improve asymmetric reduction of 4-(trimethylsilyl)-3-butyn-2-one catalyzed by immobilized Candida parapsilosis CCTCC M203011 cells</title>
        <description>Background:
Whole cells are usually employed for biocatalytic reduction reactions to ensure efficient coenzyme regeneration and to avoid problems with enzyme purification and stability. The efficiency of whole cell-catalyzed bioreduction is frequently restricted by pronounced toxicity of substrate and/or product to the microbial cells and in many instances the use of two-phase reaction systems can solve such problems. Therefore, we developed new, biphasic reaction systems with biocompatible water-immiscible ionic liquids (ILs) as alternatives to conventional organic solvents, in order to improve the asymmetric reduction of 4-(trimethylsilyl)-3-butyn-2-one (TMSB) to (S)-4-(trimethylsilyl)-3-butyn-2-ol {(S)-TMSBOL}, a key intermediate for synthesis of 5-lipoxygenase inhibitors, using immobilized Candida parapsilosis CCTCC M203011 cells as the biocatalyst.
Results:
Various ILs exerted significant but different effects on the bioreduction. Of all the tested water-immiscible ILs, the best results were observed with 1-butyl-3-methylimidazolium hexafluorophosphate (C4MIM * PF6), which exhibited not only good biocompatibility with the cells but also excellent solvent properties for the toxic substrate and product, thus markedly improving the efficiency of the bioreduction and the operational stability of the cells as compared to the IL-free aqueous system. 2-Propanol was shown to be the most suitable co-substrate for coenzyme regeneration, and it was found that the optimum volume ratio of buffer to C4MIM * PF6, substrate concentration, buffer pH, 2-propanol concentration and reaction temperature were 4/1 (v/v), 24 mM, 5.5, 130 mM and 30 degreesC, respectively. Under these optimized conditions, the maximum yield and the product e.e. wer 97.7% and &gt;99%, respectively, which are much higher than the corresponding values previously reported. The efficient whole-cell biocatalytic process was shown to be  feasible on a 250-mL scale.
Conclusions:
The whole cell-catalyzed asymmetric reduction of TMSB to (S)-TMSBOL can be substantially improved by using a C4MIM * PF6/buffer biphasic system instead of a single-phase aqueous system and the resulting biocatalytic process appears to be effective and competitive on a preparative scale.</description>
        <link>http://www.biomedcentral.com/1472-6750/9/90</link>
                <dc:creator>Wen-Yong Lou</dc:creator>
                <dc:creator>Lei Chen</dc:creator>
                <dc:creator>Bo-Bo Zhang</dc:creator>
                <dc:creator>Thomas Smith</dc:creator>
                <dc:creator>Min-Hua Zong</dc:creator>
                <dc:source>BMC Biotechnology 2009, 9:90</dc:source>
        <dc:date>2009-10-22T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6750-9-90</dc:identifier>
        <prism:publicationName>BMC Biotechnology</prism:publicationName>
        <prism:issn>1472-6750</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>90</prism:startingPage>
        <prism:publicationDate>2009-10-22T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6750/9/89">
        <title>Novel immortalized human fetal liver cell line, cBAL111, has the potential to differentiate into functional hepatocytes</title>
        <description>Background:
A clonal cell line that combines both stable hepatic function and proliferation capacity is desirable for in vitro applications that depend on hepatic function, such as pharmacological or toxicological assays and bioartificial liver systems. Here we describe the generation and characterization of a clonal human cell line for in vitro hepatocyte applications.
Results:
Cell clones derived from human fetal liver cells were immortalized by over-expression of telomerase reverse transcriptase. The resulting cell line, cBAL111, displayed hepatic functionality similar to the parental cells prior to immortalization, and did not grow in soft agar. Cell line cBAL111 expressed markers of immature hepatocytes, like glutathione S transferase and cytokeratin 19, as well as progenitor cell marker CD146 and was negative for lidocaine elimination. On the other hand, the cBAL111 cells produced urea, albumin and cytokeratin 18 and eliminated galactose. In contrast to hepatic cell lines NKNT-3 and HepG2, all hepatic functions were expressed in cBAL111, although there was considerable variation in their levels compared with primary mature hepatocytes. When transplanted in the spleen of immunodeficient mice, cBAL111 engrafted into the liver and partly differentiated into hepatocytes showing expression of human albumin and carbamoylphosphate synthetase without signs of cell fusion.
Conclusion:
This novel liver cell line has the potential to differentiate into mature hepatocytes to be used for in vitro hepatocyte applications.</description>
        <link>http://www.biomedcentral.com/1472-6750/9/89</link>
                <dc:creator>Tanja Deurholt</dc:creator>
                <dc:creator>Niek van Til</dc:creator>
                <dc:creator>Aniska Chhatta</dc:creator>
                <dc:creator>Lysbeth ten Bloemendaal</dc:creator>
                <dc:creator>Ruth Schwartlander</dc:creator>
                <dc:creator>Catherine Payne</dc:creator>
                <dc:creator>John Plevris</dc:creator>
                <dc:creator>Igor Sauer</dc:creator>
                <dc:creator>Robert Chamuleau</dc:creator>
                <dc:creator>Ronald Oude Elferink</dc:creator>
                <dc:creator>Jurgen Seppen</dc:creator>
                <dc:creator>Ruurdtje Hoekstra</dc:creator>
                <dc:source>BMC Biotechnology 2009, 9:89</dc:source>
        <dc:date>2009-10-21T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6750-9-89</dc:identifier>
        <prism:publicationName>BMC Biotechnology</prism:publicationName>
        <prism:issn>1472-6750</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>89</prism:startingPage>
        <prism:publicationDate>2009-10-21T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6750/9/88">
        <title>Regulated expression of a transgene introduced on an oriP/EBNA-1 PAC shuttle vector into human cells </title>
        <description>Background:
Sequencing of the human genome has led to most genes being available in BAC or PAC vectors. However, limited functional information has been assigned to most of these genes. Techniques for the manipulation and transfer of complete functional units on large DNA fragments into human cells are crucial for the analysis of complete genes in their natural genomic context. One limitation of the functional studies using these vectors is the low transfection frequency.
Results:
We have constructed a shuttle vector, pPAC7, which contains both the EBNA-1 gene and oriP from the Epstein-Barr virus allowing stable maintenance of PAC clones in the nucleus of human cells. The pPAC7 vector also contains the EGFP reporter gene, which allows direct monitoring of the presence of PAC constructs in transfected cells, and the Bsr-cassette that allows highly efficient and rapid selection in mammalian cells by use of blasticidin. Positive selection for recombinant PAC clones is obtained in pPAC7 because the cloning sites are located within the SacBII gene. We show regulated expression of the CDH3 gene carried as a 132 kb genomic insert cloned into pPAC7, demonstrating that the pPAC7 vector can be used for functional studies of genes in their natural genomic context. Furthermore, the results from the transfection of a range of pPAC7 based constructs into two human cell lines suggest that the transfection efficiencies are not only dependent on construct size.
Conclusion:
The shuttle vector pPAC7 can be used to transfer large genomic constructs into human cells. The genes transferred could potentially contain all long-range regulatory elements, including their endogenous regulatory promoters. Introduction of complete genes in PACs into human cells would potentially allow complementation assays to identify or verify the function of genes affecting cellular phenotypes.</description>
        <link>http://www.biomedcentral.com/1472-6750/9/88</link>
                <dc:creator>Hanne Askautrud</dc:creator>
                <dc:creator>Elisabet Gjernes</dc:creator>
                <dc:creator>Gro Storvold</dc:creator>
                <dc:creator>Mona Lindeberg</dc:creator>
                <dc:creator>Jim Thorsen</dc:creator>
                <dc:creator>Hans Prydz</dc:creator>
                <dc:creator>Eirik Frengen</dc:creator>
                <dc:source>BMC Biotechnology 2009, 9:88</dc:source>
        <dc:date>2009-10-16T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6750-9-88</dc:identifier>
        <prism:publicationName>BMC Biotechnology</prism:publicationName>
        <prism:issn>1472-6750</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>88</prism:startingPage>
        <prism:publicationDate>2009-10-16T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>
